Cervical Disc Replacement by The NASS Podcast

Cervical Disc Replacement by The NASS Podcast

Cervical Disc Replacement
Ask the Experts: A Lifelong Learning Series - October 2021 Cervical Disc Replacement Richard Guyer, MD Scott Blumenthal, MD Disclosures: Blumenthal, Scott L.: Consulting: Aesculap (C), Bayliss Medical (B), Degen Medical (C), NeoSpine (C), Orthofix (C); Device or Biologic Distribution Group (Physician-Owned Distributorship): Aesculap (A); Scientific Advisory Board: Aesculap (B), FzioMed (None); Speaking and/or Teaching Arrangements: Aesculap (D), Bayliss (None), NuVasive (None); Stock Ownership: Centinel Spine (1%), FzioMed (1%). Guyer, Richard D.: Consulting: Aescalup (C), Orthofix (D), Spinal Kinetics (B); Royalties: ATEC (B), Nanovis (D), Stryker - K2M (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
14:03
Brain-Computer Interfaces for Spinal Cord Injury - Technology Progressing Toward a Clinical Reality
Moderator Tejas Shah, MD, chats with authors Kevin Davis, BS, and Iahn Cajigas, MD, PhD, about their article, "Brain-Computer Interfaces for Spinal Cord Injury - Technology Progressing Toward a Clinical Reality."   Access the article here. Disclosures: Cajigas, Iahn: Grants: Boston Scientific (None); Stock Ownership: Kinesiometrics LLC (less than 1%). Davis, Kevin: Nothing to Disclose Shah, Tejas : Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
32:30
Controversies and Current Issues in Spinal Cord Tumors
Ask the Experts: A Lifelong Learning Series - October 2021 Controversies and Current Issues in Spinal Cord Tumors Matt Goodwin, MD Joseph Schwab, MD Daniel Sciubba, MD Disclosures: Goodwin, Matthew L.: Consulting: Augmedics (A, Outside 12-Month Requirement), JBJS Classroom (A); Fellowship Support: AOSpine (Salary), NREF (Salary); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement, Paid directly to institution/employer). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AOSpine (Travel Expense Reimbursement, Outside 24-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy Synthes (B), Medtronic (D), Stryker (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
12:28
How Can Neuromonitoring Optimize SCS Placement?
Use of neuromonitoring during spinal cord stimulator surgery varies significantly across the US. In some regions, multimodality neuromonitoring is used routinely for all procedures. In other regions, it’s rarely used at all. With more than a decade of research on the utility of IONM for SCS placement, Dr. Falowski is interviewed by Dr. Vogel about the results of his research. Richard Vogel, PhD, DABNM- Neurological Monitoring Associates, LLC, Milwaukee, WI Stephen M. Falowski, MD- St. Lukes University Health Network, Bethlehem, PA Disclosures: Falowski, Steven M.: Consulting: Abbott (F), Medtronic (E), Vertiflex (F), Vertoss (D); Stock Ownership: AGR (less than 1%), Celeri (less than 1%), Cornerloc (less than 1%), Neural Integrative Solutions (50%), Saluda (less than 1%), Spinethera (less than 1%), SPR (less than 1%), Stimgenics (less than 1%), Thermaquil (less than 1%). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President (2019-2020)); Other: NuVasive Clinical Services (Salary, employment ended May 2021); Stock Ownership: NuVasive (less than 1%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
17:31
Interview of Dr. Simon Harris: Use of Neuromonitoring in Spinal Deformity Surgery – Canadian Experience
Neuromonitoring is a widely accepted method for evaluating spinal cord and nerve root function in spinal deformity surgery; however, methods vary significantly in the US and around the world. In this episode, Dr. Simon Harris is interviewed for his perspective as an orthopedic spine surgeon who focuses on spinal deformity surgery in Toronto, Canada. Disclosures: Harris, Simon: Nothing to Disclose Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, Past President); Other: NuVasive Clinical Services (Salary). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
16:33
Collaboration with Oncology and Evolution of Targeted Therapies
Ask the Experts: A Lifelong Learning Series - October 2021 Collaboration with Oncology and Evolution of Targeted Therapies John H. Shin, MD C. Rory Goodwin, MD, PhD Joshua C. Patt, MD, MPH Disclosures: Goodwin, C. Rory: Consulting: Medtronic (B); Grants: Federal Food And Drug Administration (G, Paid directly to institution/employer), NIH/NINDS (F, Paid directly to institution/employer), Robert Wood Johnson Foundation (F, Paid directly to institution/employer). Patt, Joshua  C.: Board of Directors: AOA (Nonfinancial, Council of Orthopaedic Residency Directors Chair, Executive Committee Member). Shin, John H.: Consulting: Carbofix (None), DePuy (B), Medtronic (A), NuVasive (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
12:19
Management of Acute Spinal Cord Injury
Ask the Experts: A Lifelong Learning Series Michael Fehlings, MD, PhD, FRCSC Rajiv Saigal, MD, PhD Yi Lu, MD, PhD Disclosures: Fehlings, Michael G.: Stock Ownership: Inteligex Inc. (Future Compensation Expected). Lu, Yi: Grants: The Gillian Reny Stepping Strong Center For Trauma Innovation (E, Paid directly to institution/employer); Speaking and/or Teaching Arrangements: DePuy Synthes (B); Stock Ownership: Axiomed (less than 1%). Saigal, Rajiv: Consulting: Globus (B), Johnson & Johnson (B), Proprio (8,327 Shares). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
31:05
Impact of COVID Operating Room Restrictions on Training in the US
NASSJ editor in chief Jonathan Grauer, MD, discusses the impact of COVID operating room restrictions with article authors Tobias Mattei, MD, and Justin Zhang, MD. Access the article here. Disclosures: Grauer, Jonathan N.: Board of Directors: LSRS (Nonfinancial), NASS (Nonfinancial); Other: NASS (D).   Mattei, Tobias Alecio: Nothing to Disclose   Zhang, Justin: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
19:19
Use of MIS in Trauma
Ask the Experts: A Lifelong Learning Series Nathaniel Brooks, MD Hoon Choi, MD Nick Jain, MD Disclosures: Brooks, Nathaniel P.: Other: NASS (Nonfinancial, Minimally Invasive Procedure Section Chair). Choi, Hoon : Nothing to Disclose Jain, Nickul S.: Consulting: 4WEB (B), Centinel Spine (B), Spineart (B); Speaking and/or Teaching Arrangements: Relievant Medsystems (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:51
How to Incorporate Endoscopic Spine into Practice
Ask the Experts: A Lifelong Learning Series Nathaniel Brooks, MD Christoph Hofstetter, MD, PhD Choll W. Kim, MD, PhD Hoon Choi, MD Disclosures: Brooks, Nathaniel P.: Other: NASS (Nonfinancial, Minimally Invasive Procedure Section Chair). Hofstetter, Christoph P.: Consulting: Globus (C), Innovasis (B), Johnson & Johnson (B); Speaking and/or Teaching Arrangements: Johnson & Johnson (A), Joimax (D). Choi, Hoon : Nothing to Disclose Kim, Choll W.: Consulting: Elliquence (B), Globus (F), Spinal Elements (B), Stryker (B); Trips/Travel: Globus (D). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
20:48
Controversies in the Management of Spinal Chordoma
Ask the Experts: A Lifelong Learning Series Joseph Schwab, MD Ilya Laufer, MD Disclosures: Laufer, Ilya: Consulting: Brainlab (A), DePuy Synthes (B), Globus (B), Medtronic (C), Spine Wave (B). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AOSpine (Travel Expense Reimbursement, Outside 24-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:56
Implant in Situ Assembly
NASSJ editor in chief Jonathan Grauer, MD, chats with author Roland Roelz about his article, "Implant in situ assembly for all-posterior lumbar vertebral column resection. Technical note." Grauer, Jonathan N.: Board of Directors: LSRS (Nonfinancial), NASS (Nonfinancial); Other: NASS (D). Roelz, Roland: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
15:46
Association Between Lumbosacral Epidural Lipomatosis and Lumbosacral Epidural Steroid Injections
NASSJ editor in chief Jonathan Grauer, MD chats with author Eric Holder, MD about his paper, "Is there an association between lumbosacral epidural lipomatosis and lumbosacral epidural steroid injections? A comprehensive narrative literature review" Disclosures: Grauer, Jonathan N.: Board of Directors: LSRS (Nonfinancial), NASS (Nonfinancial); Other: NASS (D). Holder, Eric  K.: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
16:58
The Value of Visual Abstracts
NASSJ editor in chief Jonathan Grauer, MD, discusses the value of NASSJ visual abstracts with Harold Moore, MD. Disclosures: Grauer, Jonathan N.: Board of Directors: LSRS (Nonfinancial), NASS (Nonfinancial); Other: NASS (D). Moore, Harold : Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:31
Opioid Use Prior to Surgery
Author Shay Bess, MD, chats with NASSJ deputy editor Tobias Mattei, MD, about a recent NASSJ article "Opioid use prior to surgery is associated with worse preoperative and postoperative patient reported quality of life and decreased surgical cost effectiveness for symptomatic adult spine deformity; A matched cohort analysis." Disclosures: Bess, Shay: Consulting: K2M Stryker (B); Grants: DePuy Synthes (F, Paid directly to institution/employer), Globus Medical (E, Paid directly to institution/employer), Medtronic (F, Paid directly to institution/employer), NuVasive (F, Paid directly to institution/employer), SeaSpine (E, Paid directly to institution/employer), SI-BONE (D, Paid directly to institution/employer); Research Support (Staff and/or materials): Carlsmed  (E, Paid directly to institution/employer), International Spine Study Group Foundation (B); Royalties: NuVasive (B), Stryker (E). Mattei, Tobias Alecio: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
38:23
Diversity and Inclusion Among NASS Members
Moderator Alex Michael, MD, chats with Richard Skolasky, ScD, about his recent SpineLine article on diversity and inclusion among NASS members. Dr. Skolasky is chair of NASS' Diversity Task Force. Access the article here. Disclosures: Michael, Alex P: Nothing to Disclose   Skolasky, Richard L.: Board of Directors: International Society For Quality Of Life Research (Nonfinancial), North American Spine Society (Nonfinancial, Governance Committee Chair, Research Program Management Chair, voting member); Other: International Society For Quality Of Life Research (B), International Society For Quality Of Life Research (Nonfinancial, Associate Editor for Quality of Life Research).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
31:52
The Past, Present and Future of Intraoperative Neuromonitoring
Ask the Experts: A Lifelong Learning Series  Adam Doan, DC, DABNM Richard Vogel, PhD, DABNM Disclosures: Doan, Adam: Other: Nuvasive Clinical Services (Salary); Private Investments: Veridical RCM (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President (2019-2020)); Other: NuVasive Clinical Services (Salary, employment ended May 2021); Stock Ownership: NuVasive (less than 1%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
06:05
Safety and Teamwork in Neuromonitoring - Where Can We Improve
Ask the Experts: A Lifelong Learning Series - Safety and Teamwork in Neuromonitoring: Where Can We Improve? Adam Doan, DC, DABNM Richard Vogel, PhD, DABNM Disclosures: Doan, Adam: Other: Nuvasive Clinical Services (Salary); Private Investments: Veridical RCM (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President (2019-2020)); Other: NuVasive Clinical Services (Salary, employment ended May 2021); Stock Ownership: NuVasive (less than 1%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:02
The Therapeutic Value of Neuromonitoring
Ask the Experts: A Lifelong Learning Series - The Therapeutic Value of Neuromonitoring F. Todd Wetzel, MD Adam Doan, DC, DABNM Richard Vogel, PhD, DABNM Disclosures: Doan, Adam: Other: Nuvasive Clinical Services  (Salary); Private Investments: Veridical RCM (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President (2019-2020)); Other: NuVasive Clinical Services (Salary, employment ended May 2021); Stock Ownership: NuVasive (less than 1%). Wetzel, F. Todd: Other: NASS (C, Paid directly to institution/employer); Stock Ownership: Relievant Medical (40,000 Shares, 1%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:27
The Effect of Ketorolac On Posterior Minimally Invasive Lumbar Spinal Fusion
Lead Author, Chad F. Claus, DO, discusses his recent TSJ Outstanding Paper: The Effect of Ketorolac On Posterior Minimally Invasive Lumbar Spinal Fusion: An Interim Analysis from a Randomized, Double-Blinded, Placebo-Controlled Trial with Moderator Tejas Shah, MD. Access the article here: https://www.spineline-digital.org/spineline/november_december_2021/MobilePagedReplica.action?pm=2&folio=20#pg22 Disclosures: Claus, Chad: Nothing to Disclose Shah, Tejas: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
33:13
Basivertebral Nerve Ablation: Pearls and Pitfalls
Authors Gregory Moore, MD, and Will Summers, MD, discuss their recent SpineLine article, titled "Basivertebral Nerve Ablation: Pearls and Pitfalls," with moderator Renee Rosati, DO. The article first appeared in the September/October 2021 issue of SpineLine. Access the article here. Disclosures: Moore, Gregory A.: Consulting: Relievant (B), Vertos (None); Research Support (Staff and/or materials): Abbott (F, Paid directly to institution/employer), Boston Scientific (G, Paid directly to institution/employer), Relievant (D, Paid directly to institution/employer).  Summers, Will: Nothing to Disclose Rosati , Renee Michelle: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
25:15
December 09, 2021
Assessing Balance in Spine Patients: Evolution, Concept of Stability, Severity Level, and Correlation to Patient Reported Outcome Scores
Featuring: Ram Haddas, PhD, MBA, Yigal Samocha, MD, Bassel Diebo, MD Aging, vestibular deficits, neurologic conditions, neuromuscular disease, peripheral neuropathies, and abnormal spinal curvatures, all predispose an individual to postural instability and may alter their balance. Currently, most spinal surgeons rely on static radiographic parameters for objective alignment and balance data alongside patient-reported outcome measures. Radiographs have often been used as an indirect measure of balance; however, as our understanding of balance has evolved the importance of postural stability has become more appreciated. Postural stability encompasses a variety of factors including alignment, sensory inputs, muscle conditioning, and response to external stimuli. Although the ability to radiographically measure balance has significantly improved, the clinical measurements, implications, and prognosis of balance and sway have remained difficult to quantify. Disclosures: Haddas, Ram: Consulting: Medtronic (E); Grants: Alphatec (E, Outside 12-Month Requirement, Paid directly to institution/employer), Aspen Medical Products (F, Paid directly to institution/employer), Medtronic (F, Paid directly to institution/employer), SI-BONE (F, Paid directly to institution/employer), The Cervical Spine Research Society (C, Outside 12-Month Requirement, Paid directly to institution/employer). Samocha, Yigal : Nothing to Disclose Diebo, Bassel G.: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
18:07
The Future of Functional Outcome Measurements in Spine Patients
Featuring: Ram Haddas, MD, Yigal Samocha, MD, Bassel Diebo, MD Functional outcome measurements have been shown to be effective tools in diagnosing, planning treatments, and tracking outcomes in several subspecialties of medicine. The data produced from FOMs allows surgeons to tailor patient-specific surgical interventions, improve assessment of surgical outcomes, and expand the understanding of gait abnormalities and their impact on patient's daily lives. A comprehensive picture of functional outcome measurements, patient-reported outcome measures, and radiographic parameters is important for spine surgeons to understand and guide postoperative prognosis. Disclosures: Haddas, Ram: Consulting: Medtronic (E); Grants: Alphatec (E, Outside 12-Month Requirement, Paid directly to institution/employer), Aspen Medical Products (F, Paid directly to institution/employer), Medtronic (F, Paid directly to institution/employer), SI-BONE (F, Paid directly to institution/employer), The Cervical Spine Research Society (C, Outside 12-Month Requirement, Paid directly to institution/employer). Samocha, Yigal : Nothing to Disclose   Diebo, Bassel G.: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
19:05
Prediction of Survival in Patients With Spinal Metastasis
Featuring: Joseph H. Schwab, MD, MS Machine learning-based prediction decision support tools must necessarily evolve if patient outcomes involved. This is true in spinal metastases. The Sorg survival prediction algorithm is in perpetual states of validation and improvement.  Changes in the algorithm reflect changes in patient outcomes which has happened in a subset of patients particularly those who are sensitive to targeted immuno therapeutics. Disclosure: Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
04:11
Artificial Intelligence and Wearable Technology
Featuring: Joseph H. Schwab, MD, MS Artificial intelligence is becoming more integrated into every day society. Wearable technology will eventually do the same. The future of wearable technology goes far beyond its current state. Eventually the wearables will interact with other devices in our environment. Disclosure: Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
04:21
Text Neck
Featuring: Ram Haddas, MD Text neck is described as a repetitive stress injury or overuse syndrome in the neck. It is caused by prolonged use of mobile devices with the head bent down and not moving. According to recent research literature, smartphone users spend an average of two to four hours a day with their heads dropped down. This results in “700 to 1,400 hours a year of excess stress on the cervical spine. High schoolers may be most at risk, as they could spend an additional 5,000 hours per year in this position. Recently, spine providers have noticed an increase in patients with neck and upper back pain, likely related to poor posture during prolonged smartphone use. Children and adolescents may be at a higher risk and experience shoulder and arm pain, eye strain, stress, anxiety, depression and decreased school performance. Disclosure: Haddas, Ram: Consulting: Medtronic (E); Grants: Alphatec (E, Outside 12-Month Requirement, Paid directly to institution/employer), Aspen Medical Products (F, Paid directly to institution/employer), Medtronic (F, Paid directly to institution/employer), SI-BONE (F, Paid directly to institution/employer), The Cervical Spine Research Society (C, Outside 12-Month Requirement, Paid directly to institution/employer). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:11
Updates on Management of Intramedullary Spinal Tumors
The management of intramedullary spinal cord tumors remains one of the most challenging clinical problems that one encounters as a spine surgeon. Here, as part of our NASS Spinal Oncology Podcast Series, Dr. Sheng-fu Larry Lo interviews Dr. Paul McCormick and Dr. George Jallo about updates and new research on the perioperative management of these lesions, including imaging features predicting resectability, tractography, intra-operative adjuncts to guide resection, extent of resection and outcomes, and the molecular landscape of these tumors. Moderator: Hesham Soliman, MD, MSc Medical College of Wisconsin, Milwaukee, WI Chair: Sheng-fu (Larry) Lo, MHS Northwell Neurosurgery, Great Neck, NY George I. Jallo, MD Johns Hopkins Hospital, Baltimore, MD Paul McCormick, MD, MPH New York-Presbyterian Hospital-Columbia, New York, NY References: Seaman SC, Bathla G, Park BJ, Woodroffe RW, Smith M, Menezes AH, Noeller J, Yamaguchi S, Hitchon PW. MRI characteristics and resectability in spinal cord glioma. Clin Neurol Neurosurg. 2021 Jan;200:106321. Egger K, Hohenhaus M, Van Velthoven V, Heil S, Urbach H. Spinal diffusion tensor tractography for differentiation of intramedullary tumor-suspected lesions. Eur J Radiol. 2016 Dec;85(12):2275-2280. Mensah-Brown KG, Germi JW, Quattrone F, Maloney-Wilensky E, Lee JYK, Chen HI, Schuster JM. Use of Second Window ICG in spinal cord biopsy of a mildly contrast-enhancing lesion: Technical note and review of the literature. Neurochirurgie. 2021 Jun 5:S0028-3770(21)00161-2. Vetrano IG, Gennari AG, Erbetta A, Acerbi F, Nazzi V, DiMeco F, Prada F. Contrast-Enhanced Ultrasound Assisted Surgery of Intramedullary Spinal Cord Tumors: Analysis of Technical Benefits and Intra-operative Microbubble Distribution Characteristics. Ultrasound Med Biol. 2021 Mar;47(3):398-407. Forbes JA, Teschan N, Jones SH, Parry P, Simonet L, Swamy NK. Cervical corpectomy for resection of ventral intramedullary capillary hemangioma with circumferential involvement of the anterior spinal artery: case report. J Neurosurg Spine. 2018 Aug;29(2):144-149. McCormick KL, Alexiades N, McCormick PC. Microsurgical Resection of an Intramedullary Spinal Cord Hemangioblastoma Through an Anterior Cervical Approach: 2-Dimensional Operative Video. Oper Neurosurg (Hagerstown). 2021 Jan 13;20(2):E133. Ushirozako H, Yoshida G, Imagama S, Kobayashi K, Ando K, Ando M, Kawabata S, Yamada K, Kanchiku T, Fujiwara Y, Taniguchi S, Iwasaki H, Shigematsu H, Tadokoro N, Takahashi M, Wada K, Yamamoto N, Funaba M, Yasuda A, Hashimoto J, Morito S, Takatani T, Tani T, Matsuyama Y. Efficacy of Transcranial Motor Evoked Potential Monitoring During Intra- and Extramedullary Spinal Cord Tumor Surgery: A Prospective Multicenter Study of the Monitoring Committee of the Japanese Society for Spine Surgery and Related Research. Global Spine J. 2021 May 20:21925682211011443. Wang YZ, Zhang YW, Liu WH, Chai RC, Cao R, Wang B, An SY, Jiang WJ, Xu YL, Yang J, Jia WQ. Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis. Neurosurgery. 2021 May 20:nyab174. Disclosures: Jallo, George I.: Consulting: Johnson&Johnson (Financial, Honorarium for consulting on shunt design $1000/yr); Grants: Medtronic (C, Pediatric Fellowship support. THis is for the support of a pediatric neurosurgery fellow); Fellowship Support: Codman (C, This is support for the pediatric fellow, Paid directly to institution/employer). Lo, Sheng-fu Larry: Nothing to Disclose   McCormick, Paul C.: Nothing to Disclose Soliman, Hesham : Nothing to Disclose  
37:25
Hip-Spine Syndrome: Avoiding the Pitfalls
Moderator Jayesh Vallabh, MD, interviews authors Rhett MacNeille, MD, and Olumide Danisa, MD, of Loma Linda University in California about their recent SpineLine article, "Hip-Spine Syndrome: Avoiding the Pitfalls." Access the article here. Disclosures: Danisa, Olumide A.: Board of Directors: Musculoskeletal Transplantation Foundation (B, Paid directly to institution/employer); Consulting: Spineart (B); Royalties: Globus Medical (E); Trips/Travel: American Board of Orthopaedic Surgeons (B). MacNeille, Rhett : Nothing to Disclose   Vallabh, Jayesh : Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
17:47
How Did COVID-19 Affect Your Spine Tumor Practice?
How has the COVID-19 pandemic impacted your practice? What changed for you and your care team during social distancing phase? What changed for you and your care team after social distancing requirements lapsed? Join Section on Spine Oncology members John H. Shin, MD, Iliya Laufer, MD and Jacob Buchowski, MD, MS as they discuss their experiences over the past 18 months with moderator Matthew Goodwin, MD, PhD, FACSM. Disclosures: Buchowski, Jacob M.: Device or Biologic Distribution Group (Physician-Owned Distributorship): Globus Medical (E), K2M (C), Wolters Kluwer Health (A); Fellowship Support: AOSpine North America (E, Paid directly to institution/employer), OMeGA (D, Paid directly to institution/employer). Goodwin, Matthew L.: Consulting: Augmedics (A, Outside 12-Month Requirement), JBJS Classroom (A); Fellowship Support: AOSpine (Salary), NREF (Salary); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement, Paid directly to institution/employer). Laufer, Ilya: Consulting: BrainLab (A), DePuy Synthes (B), Globus (B), Medtronic (C), Spine Wave (B). Shin, John H.: Consulting: Carbofix (None), DePuy (B), Medtronic (A), NuVasive (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
21:23
August 03, 2021
Interview of Dr. Lawrence Lenke: Use of Dynamic Spinal Cord Mapping to Localize Signal Loss in Spinal Deformity Surgery
When signals are lost during surgical correction of complex spinal deformities, one available tool for localizing the site of injury is the dynamic spinal cord mapping technique. This valuable technique has gained popularity largely due to Dr. Lenke’s work in popularizing it for this purpose. In this episode, Dr. Lenke is interviewed about how he uses this technique, what information it provides, and how it influences his surgical strategy. Featuring: Richard Vogel, PhD, DABNM Co-Chair, Section on IONM Neurological Monitoring Associates, LLC, Milwaukee, WI Lawrence Lenke, MD Co-Chair, Section on Spinal Deformity Columbia University, New York, NY Disclosures: Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Other: Nuvasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Lenke, Lawrence G.: Consulting: Abryx (B), EOS TECHNOLOGY (None), Medtronic (F); Grants: Fox Family Foundation (A), Scoliosis Research Society (D, Paid directly to institution/employer); Other: AOSpine (D, Paid directly to institution/employer), Broadwater (B); Research Support (Staff and/or materials): Adult Symptomatic Lumbar Scoliosis (B, Paid directly to institution/employer), Complex CADS ISSG (E, Paid directly to institution/employer), Confirm S2AI Screw Placement By Routine Fluoroscopy (B, Paid directly to institution/employer), EOS Imaging  (A, Paid directly to institution/employer), Fox Pediatric Spinal Deformity Study (A, Paid directly to institution/employer), Scoliosis Outcome Database Registry (A, Paid directly to institution/employer), Scoli-Risk-1 (B, Paid directly to institution/employer), Tropical Application Of Tranexamic Acid To Reduce Blood Loss In Spine Surgery (E, Paid directly to institution/employer); Royalties: Medtronic (I), Quality Medical Publishing (A); Trips/Travel: AOSpine (B), Broadwater (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
19:50
ASK! Preoperative Safety Checklist Protocol in Interventional Spine Procedures
Authors Akhil Chhatre, MD, and Laryssa Richards, DO, discuss quality improvement measures their team has implemented at Johns Hopkins with moderator Renee Rosati, DO, in this episode of Spotlight on SpineLine. Access the article here. Disclosures: Chhatre, Akhil : Nothing to Disclose Rosati , Renee Michelle: Nothing to Disclose     Richards, Laryssa: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
17:10
Use of Neuromonitoring in Cervical Spine Surgery
Use of neuromonitoring in cervical spine surgery varies significantly across the US and around the world. In some regions, multimodality neuromonitoring is used routinely for all procedures. In other regions, it’s rarely used at all. In this episode, Dr. Todd Albert is interviewed for his perspective as an orthopedic spine surgeon. Disclosures: Albert, Todd J.: Board of Directors: American Orthopaedic Association (Nonfinancial, Treasurer-Elect), Hospital For Special Surgery (None, Surgeon-in-Chief Emeritus and Medical Director), Scoliosis Research Society (Nonfinancial, Past President); Consulting: Nuvasive (B); Other: JP Medical Publishers (B), Saunders/Mosby- Elsevier (B), Springer (A), Thieme Medical Publishers (B); Research Support (Staff and/or materials): PCORI (D); Royalties: DePuy Synthes Spine (F); Stock Ownership: ASIP (D), Augmedics (F), Biomerix (D, 42,253 Shares), Bonovo Orthopedics (D, 85,737 Shares), Crosstrees Medical  (D,  
19:12
The Other NASS
Moderator Jayesh Vallabh, MD, chats with NASS President Eeric Truumees, MD, about Dr. Truumees recent column in SpineLine, which outlines the differences between NASS 3 and NASS6. Dr. Truumees talks about the importance of being involved in advocacy and how your dollars are being allocated. Disclosures: Truumees, Eeric: Board of Directors: Seton Family of Doctors (None); Other Office: AAOS  (Editor-in-Chief of AAOS Now); Research Support (Staff and/or materials): Medtronic (C, Paid directly to institution/employer), Pfizer (E, Outside 12-Month Requirement, Paid directly to institution/employer), Relievant (F, Paid directly to institution/employer), Seikagaku Corporation (C, Paid directly to institution/employer), Stryker Spine (B, Outside 12-Month Requirement, Paid directly to institution/employer), Vertex Pharma (D, Outside 12-Month Requirement, Paid directly to institution/employer); Trips/Travel: AAOS (Travel Reimbursement (B). Vallabh, Jayesh : Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
19:21
Administrative Claims Databases and Neuromonitoring: What Can We Learn?
In this era of evidence-based medicine, administrative claims databases are of interest because they allow us to evaluate complex questions with large numbers; but, they also have their drawbacks. Numerous studies have used these databases to examine neuromonitoring trends in the US. What have we learned from these studies, and where should future studies focus? In this episode, Section on IONM Member, Dr. John Ney, is interviewed by IONM Co-Chair Dr. Richard Vogel, for his perspective as a neurologist and health policy expert. Disclosures: Ney, John: Board of Directors: ASNM (A); Consulting: Ceribell  (C), Ceribell (B); Other Office: American Academy of Neurology, Medical Economics and Management Committee (Travel reimbursement). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Other: Nuvasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
20:14
Effect of Spinal Manipulative and Mobilization Therapies in Young Adults with Low Back Pain
Moderator Erik Westerlund, MD discusses the 2020 JAMA article, "Effect of spinal manipulative and mobilization therapies in young adults with mild to moderate chronic low back pain: a randomized clinical trial" with Literature Review authors Ryan L. McLean, BS and Jonathan N. Grauer, MD. Access the article here. Disclosures: Grauer, Jonathan N.: Board of Directors: LSRS (Nonfinancial, committee/board role); Other: NASS (D). McLean, Ryan L.: Nothing to Disclose Westerlund, Erik: Consulting: Nuvasive (B); Research Support (Staff and/or materials): Seaspine (None, Research support); Scientific Advisory Board: Seaspine (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
21:48
Neuromonitoring Societies: Who Are They and What Are They Working On?
Who are the different neuromonitoring societies, what role(s) do they play in patient care, where are they focusing their efforts, and what opportunities are there for inter-society collaboration? In this episode, NASS IONM Section Co-Chair, Dr. Richard Vogel, is interviewed in his role as Past-President of the American Society of Neurophysiological Monitoring (ASNM). Disclosures: Doan, Adam: Other: Nuvasive Clinical Services  (Salary); Private Investments: Veridical RCM (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Other: Nuvasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:41
Neuromonitoring: State of the Art in 2021 and Beyond
How many surgeries are monitored in the US each year? What portion are spine? Is use of IONM increasing or decreasing? What major trends do we see in the use of IONM in spine surgery, and what can we expect in the future? This episode hosted by Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan will answer all of these questions and more! Disclosures: Doan, Adam: Other: Nuvasive Clinical Services  (Salary); Private Investments: Veridical RCM (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Other: Nuvasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
16:33
Preventing Blood Loss in Spine Surgery with Tranexamic Acid
Featuring: Moderator Alex Michael, MD and Author James Reynolds, MD James Reynolds, MD, co-chair of NASS' Patient Safety Committee, discusses Preventing Blood Loss in Spine Surgery with Tranexamic Acid. Reducing blood loss during spine surgery is one of the many responsibilities of spine surgeons to keep patients safe. Dr. Reynolds addresses this and more in the latest episode discussing an article that recently appeared in SpineLine. Access the article here.  Disclosures: Michael, Alex P: Nothing to Disclose   Reynolds, James B.: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
16:12
New Interventional Spine & Musculoskeletal Medicine Fellowships
Featuring: Moderator Renee Rosati, DO and Author David O'Brien, Jr., MD. NASS Treasurer David O'Brien, Jr., MD, discusses new Interventional Spine & Musculoskeletal Medicine Fellowships and the opportunities they will afford young physicians. Dr. O'Brien touches on NASS completing its inaugural ISMM fellowships with a 100% match, and more in this podcast with moderator Renee Rosati, DO. Access the SpineLine article here. Disclosures: O'Brien, David Reese: Nothing to Disclose   Rosati, Renee Michelle: Nothing to Disclose  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
24:36
Where Are We Headed with Endoscopic Spine Surgery
Featuring: Jin Sun Kim, MD and Michael Y. Wang, MD Disclosures: Kim, Jin Sun: Stock Ownership: Innovasive (1%); Consulting: Richard Wolf (Travel Expense Reimbursement), Elliquence (Travel Expense Reimbursement); Scientific Advisory Board: Innovasive (Nonfinancial); Grants: AOSpine (A). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (1%), Medical Device Partners (1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:60
How to Minimize the Burden of Fusion with ERAS
Featuring: Michael Y. Wang, MD and Daniel K. Resnick, MD Disclosures: Resnick, Daniel: Scientific Advisory Board: NIDUS (None). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (1%), Medical Device Partners (1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:03
Stem Cell Therapies in the Treatment of Disc-Related Low Back Pain
Moderator Douglas Pahl, MD, interviews authors Alex Mierke, MD, and Omar Ramos, MD, about their article titled, "Stem Cell Therapies in the Treatment of Disc-Related Low Back Pain." Drs. Mierke and Ramos discuss what is already known about stem cell therapies and what still may lie ahead in this ever-changing medical landscape. Access the article here. Disclosures: Mierke, Alex : Nothing to Disclose   Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (less than 1%), Vertera (D, Paid directly to institution/employer); Trips/Travel: Astrazeneca (A, Outside 12-Month Requirement), Boston Scientific (B, Outside 12-Month Requirement), DePuy/Synthes (A, Outside 12-Month Requirement), DJO (A, Outside 12-Month Requirement), Globus (A, Outside 12-Month Requirement), Horizon (A, Outside 12-Month Requirement), Medtronic (A, Outside 12-Month Requirement), Stryker (B, Outside 12-Month Requirement), Zimmer/Biomet (C, Outside 12-Month Requirement). Ramos, Omar: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
28:43
Considerations for Spinal Fusion Surgery in the Elderly: Osteoporosis, Sarcopenia & Frailty
Featuring: Joseph S. Butler, PhD, FRCS and Arjun S. Sebastian, MD Disclosures: Butler, Joseph S.: Nothing to Disclose (Sep 26, 2019).   Sebastian, Arjun S.: Nothing to Disclose (Feb 04, 2019) Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:06
ALIF: Stand Alone and When to Back Up
Featuring: Mark M. Mikhael, MD; Deepak Reddy, MD; Bradley Saitta, MD; Nick Shamie, MD Disclosures: Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B). Reddy, Deepak: Nothing to Disclose. Saitta, Bradley: Nothing to Disclose. Shamie, Nick: Royalties: Seaspine (B); Stock Ownership: SI Bone (100000 Shares, 1%), Vertiflex (200000 Shares, 1%); Consulting: Stryker (Financial, 0), Seaspine (Financial, 0), SI Bone (Financial, 0), Vertiflex (Financial, 0); Speaking and/or Teaching Arrangements: Medtronic (Financial, 0); Trips/Travel: Medtronic (Financial, 0); Board of Directors: Vertiflex (Financial, Medical Director); Scientific Advisory Board: SI Bone (Financial, Medical Advisory Board). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:38
Use of Mesenchymal Cellular Bone Matrix in Complex Cervical Surgery
Featuring: Mark M. Mikhael, MD; Deepak Reddy, MD; Bradley Saitta, MD; Nick Shamie, MD Disclosures: Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B).  Reddy, Deepak: Nothing to Disclose.   Saitta, Bradley: Nothing to Disclose. Shamie, Nick: Royalties: Seaspine (B); Stock Ownership: SI Bone (100000 Shares, 1%), Vertiflex (200000 Shares, 1%); Consulting: Stryker (Financial, 0), Seaspine (Financial, 0), SI Bone (Financial, 0), Vertiflex (Financial, 0); Speaking and/or Teaching Arrangements: Medtronic (Financial, 0); Trips/Travel: Medtronic (Financial, 0); Board of Directors: Vertiflex (Financial, Medical Director); Scientific Advisory Board: SI Bone (Financial, Medical Advisory Board).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:60
Graft Selection for Interbody Fusion
Featuring: Zoher Ghogawala, MD; Han Jo Kim, MD; Khoi D. Than, MD Disclosures: Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Chair).   Kim, Han Jo: Board of Directors: AOSpine (B); Fellowship Support: AOSpine (D, Paid directly to institution/employer); Research Support (Staff and/or materials): CSRS (C, Outside 12-Month Requirement, Paid directly to institution/employer), ISSGF (C, Paid directly to institution/employer); Royalties: K2M (D), Zimmer Biomet (F).   Than, Khoi D.: Consulting: Bioventus (B), Medtronic (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:05
Spinal Masqueraders
Featuring: Evan K. Johnson, PT, DPT, OCS and Rick J. Placide, MD, PT Disclosures: Johnson, Evan K. : Nothing to Disclose.   Placide, Rick J. : Nothing to Disclose. Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:32
Navigating the Job Search for Spine Specialists
Featuring: Sandeep N. Gidvani, MD and Nickul Jain, MD Disclosures: Gidvani, Sandeep N.: Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).   Jain, Nickul: Consulting: Spineart (Future Compensation Expected); Research Support (Staff and/or materials): Globus Medical (Nonfinancial). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:28
How to Choose Between Posterior Interbody Fusions Versus Lateral Interbody Fusion
Featuring: Sandeep N. Gidvani, MD and Paul R. Gause, MD Disclosures: Gause, Paul R. : Speaking and/or Teaching Arrangements: Medtronic (C).  Gidvani, Sandeep N. : Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:07
Marketing Masquerading as Medical Information
Featuring: E. Kano Mayer, MD; Eeric Truumees, MD; Mark Cuccuzella, MD Disclosures: Cuccuzella, Mark: Nothing to Disclose. Mayer, E. Kano: Stock Ownership: Infinite Orthopedics (1%); Private Investments: Lanai Health Solutions (30%); Speaking and/or Teaching Arrangements: North America Spine Society (B); Trips/Travel: NASS (B).   Truumees, Eeric: Trips/Travel: AAOS (Travel Expense Reimbursement); Board of Directors: Seton Family of Doctors (Salary); Other Office: AAOS Communications Cabinet (E, Travel Expense Reimbursement, Editor-in-Chief of AAOS Now); Research Support - Staff and/or Materials: Relievant (B, Paid directly to institution/employer), Medtronic (A), Vertex Pharma (A), Dova Pharmaceuticals (A), Pfizer (B, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:20
Stem Cells and Degenerative Disc Disease
Featuring: Zorica Buser, PhD and Mark Erwin, DC, PhD Disclosures: Buser, Zorica: Consulting: AOSpine (B, Outside 12-Month Requirement), Xenco Medical (B, Outside 12-Month Requirement); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): Next Science (F, Paid directly to institution/employer), SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AO Spine (Travel reimbursements for AO Spine Knowledge forum meetings and congresses).   Erwin, Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:02
Use of Bone Cement in Metastatic Spinal Disease and Beyond
Featuring: Matthew L. Goodwin, MD, PHD (Washington University), Dan Sciubba, MD (Johns Hopkins), and Joe Schwab, MD, MS (Harvard/Massachusetts General Hospital) Use of bone cement in the spine has been marred by early controversy, including debate over kyphoplasty/vertebroplasty and whether use of bone cement in spine surgery was safe or effective.  Now with recent publications reviewing almost 20 years of cement use in the spine, the data are relatively convincing that bone cement in spine surgery is not only useful, but also relatively safe.   In this podcast, these spine tumor surgeons from NASS' Section on Spine Oncology discuss the history of bone cement in the spine, the current use/indications for cement (e.g. metastatic spinal disease, osteoporosis), current techniques (e.g. through fenestrated pedicle screws), and discuss potential complications as well as practical tips for employing these techniques. Disclosures: Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy-Synthes (B), Globus (B), Medtronic (C), Nuvasive (B), Stryker (C). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
17:26
Identifying and Managing Physician Burnout in Today’s Health Care Environment
Did you know that physicians, as a group, have lower work-life satisfaction compared to the general population? The consequences of burnout are borne both by the individual physician and the health care system. The recognition of burnout as a serious individual and institutional challenge is leading to an increased need to design, implement, and evaluate systems that promote well-being. Moderator Richard L. Skolasky, Jr., Sc.D. interviews Todd Albert, MD and Eric Muehlbauer, MJ, CAE on this very important topic to assist the listener in ultimately being able to identify and strategize to mitigate risk factors in their own lives or in the organization that they represent. Disclosures: Albert, Todd J.: Board of Directors: American Orthopaedic Association (Nonfinancial, Treasurer-Elect), Hospital For Special Surgery (None, Surgeon-in-Chief Emeritus and Medical Director), Scoliosis Research Society (Nonfinancial, Past President); Consulting: Nuvasive (B); Other: JP Medical Publishers (B), Saunders/Mosby- Elsevier (B), Springer (A), Thieme Medical Publishers (B); Research Support (Staff and/or materials): PCORI (D); Royalties: DePuy Synthes Spine (F); Stock Ownership: ASIP (D), Augmedics (F), Biomerix (D, 42,253 Shares), Bonovo Orthopedics (D, 85,737 Shares), Crosstrees Medical  (D,  
24:08
Optimizing the High Risk Patient for Surgery and Burnout
Featuring: F. Todd Wetzel, MD; Carrie A. Diulus, MD; Mark Cuccuzella, MD Disclosures: Cuccuzella, Mark : Nothing to Disclose Diulus, Carrie A. : Trips/Travel: NASS (Travel Expense Reimbursement).   Wetzel, F. Todd : Stock Ownership: Relievant Medical (1%).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:10
Spinal Cord Mapping
Featuring: Lawrence G. Lenke, MD; Evan K. Johnson, PT, DPT, OCS; Neel Anand, MD Disclosures: Anand, Neel: Royalties: Medtronic (F), Nuvasive (B), Globus Medical (B), Elsevier (B); Stock Ownership: Globus (, unknown), Medtronics (, unknown); Private Investments: Paradigm Spine (, 1%, unknown), Bonovo Orthopaedics (, 1%, unknown), Pearl Diver (, 1%, unknown), Theracell (, 1%, unknown), GYS Tech (, 1%, unknown); Consulting: Spinal solutions (Financial, Stock options : Unknown ); Speaking and/or Teaching Arrangements: Medtronic (Financial, 42000); Trips/Travel: Medtronic (Financial, Included with consulting fees); Scientific Advisory Board: Globus Medical (Financial, 0). Johnson, Evan K. : Nothing to Disclose. Lenke, Lawrence G.: Consulting: DePuy Synthes (D, Outside 12-Month Requirement), K2M (D, Outside 12-Month Requirement), Medtronic (I, Outside 12-Month Requirement, Paid directly to institution/employer); Device or Biologic Distribution Group (Physician-Owned Distributorship): Medtronic (I), Quality Medical Publishing  (A); Grants: Fox Family Foundation (A); Other: AOSpine (D, Paid directly to institution/employer), Broadwater (B), Scoliosis Research Society (B), The Spinal Research Foundation (Travel Expense Reimbursement); Research Support (Staff and/or materials): EOS Imaging (A), Setting Scoliosis Straight Foundation (A).     Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:59
Augmented Reality, Virtual Reality and Artificial Intelligence: Are We There Yet?
Moderator Douglas Pahl, MD interviews Karthik Madhavan, MD about a SpineLine articled he helped author titled, "Augmented Reality, Virtual Reality and Artificial Intelligence: Are We There Yet?". Dr. Madhavan talks about the exciting developments with augmented reality and how there is still much to learn in the cutting-edge technology. This article first appeared in the January/February 2020 edition of SpineLine. Access the article here.  Disclosures: Madhavan, Karthik : Nothing to Disclose   Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (
30:28
Epidural Abscess
Featuring: Joseph H. Schwab, MD; Andrew J. Schoenfeld, MD Disclosures: Schoenfeld, Andrew J.: Royalties: Wolters Kluwer, Springer (B); Consulting: ArborMetrix (C); Trips/Travel: JBJS (A); Other Office: Journal of Bone and Joint Surgery (C); Research Support - Staff and/or Materials: CMS (D, Paid directly to institution/employer); Grants: Department of Defense (D, Paid directly to institution/employer), OREF (D, Paid directly to institution/employer), NIH (F, Paid directly to institution/employer).   Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:38
Survival Prediction and Frailty Evaluation for Patients with Metastatic Tumors
Featuring: Joseph H Schwab, MD; Dan M Sciubba, MD; Ilya Laufer, MD Disclosures: Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AOSpine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement).  Sciubba, Dan: Consulting: Baxter (B), DePuy Synthes (B), Globus (B), Medtronic (C), NuVasive (B), Stryker (C).   Laufer, Ilya : Consulting: BrainLab (A), DePuy Synthes (B), Globus (B), Medtronic (C), SpineWave (B).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:00
Value-Based Gap Analysis of Neuromonitoring
Featuring: F. Todd Wetzel, MD, John Ney, MD, Tara Stewart, PhD, DABNM Disclosures: Wetzel, F. Todd: Stock Ownership: Relievant Medical (1%).  Ney, John: Board of Directors: American Society for Neuromonitoring (None); Consulting: Ceribell (B), SpecialtyCare (B); Other Office: American Academy of Neurology, Medical Economics and Management Committee (Travel Expense Reimbursement); Speaking and/or Teaching Arrangements: SpecialtyCare (Travel Expense Reimbursement).  Stewart, Tara: Private Investments: IONM Life LLC (Future Compensation Expected, Paid directly to institution/employer) Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:27
Lumbar Disc Replacement
Featuring: Scott Blumenthal, MD, Richard D. Guyer, MD, Jack E. Zigler, MD Disclosures: Blumenthal, Scott: Royalties: Aesculap (A); Stock Ownership: FzioMed (1%), VertiFlex (1%), Centinel Spine (1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).  Richard D. Guyer, MD: Royalties: Alphatec (B); Stock Ownership: Spinal Motion (None); Private Investments: Spinal Ventures I and II (5%); Consulting: DePuy/Synthes (B); Speaking and/or Teaching Arrangements: Synthes (None); Scientific Advisory Board: K2M (B), Spinal Kinetics (Stock options), Nanovis (Stock options), Crocker Technologies (None), MiMedx (None); Fellowship Support: NuVasive (D, Paid directly to institution/employer).  Jack E. Zigler, MD: Consulting: Aesculap (C), Centinel Spine (C), FloSpine (B), Medtronic Spine (B), Orthofix (B), Simplify Medical (B); Royalties: Zimmer Spine (B); Scientific Advisory Board: Safe Orthopedics (Future Compensation Expected). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:20
Psychologically Informed Practice
Featuring: F. Todd Wetzel, MD, Chris J. Main, MA, PhD, Gregory L. Whitcomb, DC Disclosures: Wetzel, F. Todd: Stock Ownership: Relievant Medical (1%).  Main, Chris J.: Consulting: Medrisk Inc International Scientific Advisory Board (B, Paid directly to institution/employer); Device or Biologic Distribution Group (Physician-Owned Distributorship): The Back Book (B).  Whitcomb, Gregory L.: Speaking and/or Teaching Arrangements: North American Spine Society (B); Trips/Travel: North American Spine Society (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
12:21
Cervical Disc Replacement
Featuring: Scott Blumenthal, MD, Richard D. Guyer, MD, Jack E. Zigler, MD Disclosures: Blumenthal, Scott: Royalties: Aesculap (A); Stock Ownership: FzioMed (1%), VertiFlex (1%), Centinel Spine (1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).  Guyer, Richard D.: Royalties: Alphatec (B); Stock Ownership: Spinal Motion (None); Private Investments: Spinal Ventures I and II (5%); Consulting: DePuy/Synthes (B); Speaking and/or Teaching Arrangements: Synthes (None); Scientific Advisory Board: K2M (B), Spinal Kinetics (Stock options), Nanovis (Stock options), Crocker Technologies (None), MiMedx (None); Fellowship Support: NuVasive (D, Paid directly to institution/employer).  Zigler, Jack E.: Consulting: Aesculap (C), Centinel Spine (C), FloSpine (B), Medtronic Spine (B), Orthofix (B), Simplify Medical (B); Royalties: Zimmer Spine (B); Scientific Advisory Board: Safe Orthopedics (Future Compensation Expected). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:30
Section on IONM: How to Optimize Neuromonitoring Episode 12
[12 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Are wakeups always prolonged with neuromonitoring under TIVA?” It’s a common complaint: we use TIVA for MEPs, but the patients take forever to wake up from anesthesia. To combat this problem, many surgeons elect to discontinue IONM earlier in the procedure. Did you know IONM has the technology to guide the anesthesia team through a faster wakeup in most cases? It requires communication and collaboration, but it’s easy to do. Here we review these techniques. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:34
Operating on Neurofibromas- What Have We Learned?
[3 of 3] In this newest episode from the Section on Spine Oncology , Drs. Schwab, Sciubba, and Goodwin discuss operating on neurofibromas.  Surgery on patients with neurofibromas can range from relatively straightforward (simple neurofibromas) to life-threatening (complex plexiform neurofibromas).  In patients with plexiform neurofibromas, particularly those near the spinal cord, care needs to be taken preoperatively, when considering surgical indications, as well as intra-operatively, where hemostasis can become challenging.   Disclosures: Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement),  Stryker Spine (B, Outside 12-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy Synthes (B), Globus (B), Medtronic (C), NuVasive (B), Stryker (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:35
Se

Images Powered by Shutterstock